MRK Merck & Company Inc
Company Analysis
Latest News
Wells Fargo Raises Merck Target to $170, Citing $5B Heart Drug Potential
Wells Fargo raised its price target for Merck & Co. to $170 from $150. The firm maintained an overweight rating on the shares. This target represents a...
Merck Faces Future Keytruda Competition as Cipla and Qilu Partner for US Biosimilar Launch
India's Cipla and China's Qilu Pharmaceutical announced a partnership for a Keytruda biosimilar in the United States. This creates a new competitive threat for...
🔴 Merck is trading 12% down in after-hours trading with no clear company-specific catalyst
Merck is trading at $132.35, with a -11.50% change and no clear company-specific announcement, earnings release, or regulatory event explaining the after-hours...
🟢 Merck is trading 3.1% up today with no clear new catalyst
Merck is trading at $155.28, up +3.06% (about 3.1%), with no clear new catalyst; recent bullish analyst target increases and positive oncology-trial momentum...
Merck Fails to Block Medicare Price Talks, Judge Rules Participation Voluntary
A federal judge in Washington, D.C. dismissed Merck’s lawsuit challenging the government’s authority to negotiate Medicare drug prices. This ruling upholds a...
🟢 Merck is trading 3.11% up today after cancer vaccine met both Phase 3 endpoints
Merck is trading at $153.63 (+3.11%) after its jointly developed cancer vaccine with Moderna met both Phase 3 melanoma endpoints. - INTerpath-001 showed...
Merck Downgraded by RBC on 'Unprecedented Valuation' Following Stock Rally
RBC Capital downgraded Merck & Co. (MRK) to "Sector Perform" from "Outperform." The firm cited valuation concerns after the stock's recent surge. RBC...
🟢 Merck is trading 10% up today after positive Phase 3 melanoma vaccine results
Merck is trading 10.44% up now at $149.42 after Merck and Moderna announced positive Phase 3 INTerpath-001 results for intismeran combined with Keytruda. -...
🟢 Merck is trading 12% up today after positive Phase 3 melanoma vaccine results
Merck is trading at $151.09 (+11.74%) after Merck and Moderna reported positive Phase 3 results for personalized mRNA cancer vaccine intismeran combined with...
Merck's mRNA Cancer Vaccine Breakthrough Sends Shares Surging — But Can a Personalized Shot Offset a $32 Billion Patent Cliff?
Shares of Merck vaulted 10% to $148.64 Wednesday morning after the pharma giant and partner Moderna reported that their personalized mRNA cancer vaccine hit...
🟢 Merck is trading 9.39% up today after positive Phase 3 personalized mRNA melanoma vaccine results
Merck is trading 9.39% up at $148.64 after Merck and Moderna announced positive Phase 3 results for their personalized mRNA melanoma vaccine. - Combined with...
Merck Slams Germany’s New Drug Rebates, Citing Stifled Domestic Investment
The German government approved new healthcare spending controls on August 18, 2026. These measures aim to save billions of euros by increasing mandatory...
Merck eyes 2026 oncology milestone, seeking growth beyond Keytruda
Merck & Co., Inc. faces a significant regulatory action date on August 17, 2026, for a new oncology application. This milestone serves as a critical test of...
🔴 Merck is trading 3.86% down in after-hours trading — catalyst remains unclear
Merck is trading at $125.87, down -3.86% in after-hours trading, with no new August 10, 2026 company-specific announcement clearly explaining the decline. -...
Merck's second quarter revenue of $16.6B beat estimates, driven by strong Keytruda sales and an upgraded FY2026 outlook.
Merck reported second quarter 2026 revenue of $16.6 billion, a 5% year-over-year increase that surpassed analyst expectations. The company posted a non-GAAP...
Merck & Company Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Merck & Company is expected to report Q2 2026 revenue of $16.33 billion and a consensus EPS loss of $0.26, while the current $130.20 share price sits below the...
Merck Target Raised to $150 by Barclays Following Record Highs
Barclays raised its price target for Merck & Co. to $150 from $140. The firm maintained its Overweight rating on the stock. The revision follows a period of...
🟢 Merck is trading 3.1% up today as it rebounds amid a healthcare sector rally
Merck is trading at $134.78 (3.1% up) as it rebounds from an unexplained after-hours drop yesterday, gaining support from a broader move into healthcare...
🔴 Merck is trading 4.44% down today with no company-specific catalyst identified
Merck is trading at $124.96 (4.44% down) in after-hours trading following a regular-session close of $130.76, with no immediate company-specific news or...
Merck Inks Royalty-Free Deals for Experimental HIV Pill in 129 Countries
Merck & Co. signed seven non-exclusive, royalty-free voluntary licensing agreements with generic drug manufacturers. These agreements cover its experimental...